

REMARKS

Claims 1-13 are pending in the present application.

The Abstract, specification, claim heading, and claims 1 and 5 have been amended, and claims 6-13 have been added. Reconsideration of the application, as amended, is respectfully requested.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the application by this Amendment.

In the event that any outstanding matters remain in this application, the Examiner is invited to contact the undersigned at (702) 205-8000 in the Washington, D.C. area.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Joe McKinney Muncy
Joe McKinney Muncy, #32,334

KM/asc
3854-0102P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments

(Rev. 09/27/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Abstract of the Disclosure:

The Abstract of the Disclosure has been moved from the bottom of page 8 (the last page of claims) to new page 9 (a new page following the last page of claims), and has been amended as follows:

--Abstract of the Disclosure

A method for countering oxidization of low density lipoproteins, reducing cholesterol or triglyceride in plasma or inhibiting atherosclerosis comprising administering an effective amount of a Hibiscus sabdariffa extract.--

IN THE SPECIFICATION

A paragraph has been added after the heading beginning on page 2, line 9.

IN THE CLAIMS:

The heading of the claims has been amended as follows:

[Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract

Claims]

What is claimed is:

The claims have been amended as follows:

5. (Amended) The method of claim 1[, 2, 3 or 4 wherein], further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.

09989490-112101

8. (Amended) The method of claim 2[, 3 or 4], wherein the administering to a human being is accomplished by a daily dose of from about 5 g to about 50 g.

Claims 9-13 have been added.

09989490.112101